U.S. markets closed


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.28-0.01 (-0.19%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close5.29
Bid5.12 x 1400
Ask5.29 x 1100
Day's Range5.19 - 5.39
52 Week Range0.97 - 5.39
Avg. Volume106,853
Market Cap138.797M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IMRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IMARA Inc.
    Daily – Vickers Top Buyers & Sellers for 01/03/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • American City Business Journals

    Struggling blood disorder biotech shuts down via reverse merger

    Imara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech.

  • Benzinga

    Imara Agrees To Merge With Precision Oncology Player, Shares Surge

    Enliven Therapeutics Inc and Imara Inc (NASDAQ: IMRA) agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001 for chronic myeloid leukemia. ELVN-002 for HER2 mutant lung cancer and other HER2-driven tumor types. In September, Imara divested tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuti

  • GlobeNewswire

    Enliven Therapeutics and Imara Announce Merger Agreement

    Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additiona